Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: Comparison between different assays for the detection of antiphospholipid antibodies

Thrombosis and Haemostasis

Volumn 76, Issue 6, 1996, Pages 916-924

  Horbach, Daniëlle A ^a   Oort, Erica V ^a   Danders, Richard C J M ^a   Derksen, Ronald H W M ^a   De Groot, Philip G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIGEN BINDING; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; GLYCOPROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 0030457493     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Love PE, Santoro SA, Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
2. Harris EN, Asherson RA, Hughes GR. Antiphospholipid antibodies-autoantibodies with a difference. Annu Rev Med 1988; 39: 261-71.
3. de Groot PG, Oosting JD, Derksen RHWM. Antiphospholipid antibodies: specificity and pathophysiology. Bailliere's Clin Haematol 1993; 6: 691-709.
4. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84: 2854-67.
5. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein factor. Lancet 1990; 335: 1544-7.
6. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 41204.
7. 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
8. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
9. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-92.
10. 2-glycoprotein and anticardiolipin antibodies. J Rheumatol 1995; 22: 2233-7.
11. Kaburaki J, Kuwana M, Ikeda Y, Yamamoto M, Kawai S, Matsuura E. Cofactor (β-glyccprotein I) dependent anticardiolipin antibodies and thrombosis [letter]. J Rheumatol 1994; 21: 1371-2.
12. 2-glycoprotein I antibodies: Detection and association with thrombosis. Br J Haematol 1995; 89: 397-402.
13. 2-glycoprotein I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91:471-3.
14. 2-glycoprotein I antibodies in HIV infection. Clin Immunol Immunopathol 1995; 77: 69-74.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
17. 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66: 666-71.
18. 2-Glykoprotein I-Mangel. Humangenetik 1968; 5: 291-3.
19. Fujikawa K, Thompson AR, Legaz ME, Meyer RG, Davie EW. Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry 1973; 12: 4938-45.
20. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-9.
21. Derksen RH, Hasselaar P, Blokzijl L, Gmelig Meyling FH, de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-71.
22. Comfurius P, Bevers EM, Galli M, Zwaal RF. Regulation of phospholipid asymmetry and induction of antiphospholipid antibodies. Lupus 1995; 4 Suppl 1:S19-22.
23. Tax WJM, Kramers C, Van Bruggen MCJ, Berden JHM. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995; 48: 666-73.
24. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus (see comments). Am J Med 1992; 93:181-6.
25. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.